

18-02-02

1635

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	09/900,425
Filing Date	07/06/2001
First Named Inventor	Hongjiang Wu and Stanley T. Crooke
Group Art Unit	1635
Examiner Name	Sean McGarry
Attorney Docket Number	ISIS-0003-100(ISIS-5029)

Total Number of Pages in This Submission **3**

## ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

Remarks

Express Mail No. EV147 552 812US  
Date of Deposit: September 30, 2002

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name: Gwilym John Owen Attwell, Registration No. 45,449  
Cozen O'Connor, P.C., Customer No. 34138

Signature

Date

September 30, 2002

RECEIVED

OCT 07 2002

TECH CENTER 1600/2900

## CERTIFICATE OF MAILING


I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date:

Typed or printed name

Signature

Date

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



#13/K.T.  
10/7

ELECTION

Docket No.: ISIS-0003-100 (ISIS-5029)

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Wu *et al.*

Serial No.: 09/900,425

Group Art Unit: 1635

Filed: July 6, 2001

Examiner: S. McGarry

Title: HUMAN RNASE III AND COMPOSITIONS AND USES THEREOF

Express Mail Number: EV147 552 812US

Deposited: September 30, 2002

Assistant Commissioner for Patents  
Washington, D.C. 20231

RECEIVED

OCT 07 2002

Dear Sir:

TECH CENTER 1600/2900

RESPONSE

This paper is filed in response to the Office Action dated August 29, 2002.

REMARKS

Claims 1-52, all the pending claims, are subject to a restriction requirement.

The Examiner required Applicants to elect one of twelve patentably distinct inventions for examination. The Office Action alleges that each of the inventions is distinct because, *inter alia*, "they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects." (Office Action at page 5).

Applicants elect herein Group I with traverse, encompassing claims 1-4, and 19, "drawn to a RNase III protein and compositions comprising RNase III protein, classifiable in class 530, subclass 350".